Noninsulin Treatment of Type 2 Diabetes Mellitus in Geriatric Patients: A Review

Clinical Therapeutics

Volumn 33, Issue 12, 2011, Pages 1868-1882

  Germino, F Wilford ^a  

^a Orland Primary Care Specialists LLC   (United States)

Author keywords

Elderly; Exenatide; Incretin; Liraglutide; Type 2 diabetes mellitus

Indexed keywords

ACARBOSE; ALPHA GLUCOSIDASE INHIBITOR; ANTIDIABETIC AGENT; COLESEVELAM; DIPEPTIDYL PEPTIDASE IV INHIBITOR; EXENDIN 4; GLIBENCLAMIDE; GLIBENCLAMIDE PLUS METFORMIN; GLIMEPIRIDE; GLIMEPIRIDE PLUS PIOGLITAZONE; GLIMEPIRIDE PLUS ROSIGLITAZONE; GLIPIZIDE; GLIPIZIDE PLUS METFORMIN; GLITAZONE DERIVATIVE; GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; HEMOGLOBIN A1C; LINAGLIPTIN; LIRAGLUTIDE; METFORMIN; METFORMIN PLUS PIOGLITAZONE; METFORMIN PLUS REPAGLINIDE; METFORMIN PLUS ROSIGLITAZONE; METFORMIN PLUS SAXAGLIPTIN; METFORMIN PLUS SITAGLIPTIN; MIGLITOL; NATEGLINIDE; ORAL ANTIDIABETIC AGENT; PIOGLITAZONE; REPAGLINIDE; ROSIGLITAZONE; SAXAGLIPTIN; SITAGLIPTIN; SULFONYLUREA DERIVATIVE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ACUTE HEART INFARCTION; ACUTE PANCREATITIS; AGED; BLADDER CANCER; BONE DENSITY; CARDIOVASCULAR DISEASE; CREATININE CLEARANCE; DIABETIC DIET; DIARRHEA; DOSE RESPONSE; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; DYSLIPIDEMIA; EMBASE; GASTROINTESTINAL SYMPTOM; GERIATRIC PATIENT; GLYCEMIC CONTROL; HEART FAILURE; HEART MUSCLE ISCHEMIA; HUMAN; HYPOGLYCEMIA; IMPAIRED GLUCOSE TOLERANCE; INSULIN SENSITIVITY; KIDNEY FAILURE; KIDNEY FUNCTION; LACTIC ACIDOSIS; MEDLINE; META ANALYSIS (TOPIC); MONOTHERAPY; MULTICENTER STUDY (TOPIC); NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; PERIPHERAL EDEMA; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECOMMENDED DRUG DOSE; RETINA MACULA EDEMA; REVIEW; RHINOPHARYNGITIS; RISK FACTOR; SIDE EFFECT; SYSTEMATIC REVIEW (TOPIC); SYSTOLIC BLOOD PRESSURE; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; VOMITING; WEIGHT GAIN; WEIGHT REDUCTION;

AGE FACTORS; AGED; AGING; BIOLOGICAL MARKERS; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; EVIDENCE-BASED MEDICINE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; PATIENT SELECTION; RISK ASSESSMENT; RISK FACTORS; TREATMENT OUTCOME;

EID: 83455210444     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2011.10.020     Document Type: Review

References (95)

1. National diabetes fact sheet: national estimates and general information on diabetes and prediabetes in the United States, 2011 Centers for Disease Control and Prevention, Accessed March 22, 2011. http://www.cdc.gov/diabetes/pubs/pdf/ndfs_2011.pdf.
2. Number (in millions) of civilian, non-institutionalized persons with diagnosed diabetes, United States, 1980-2008 Centers for Disease Control and Prevention, Accessed March 14, 2011. http://www.cdc.gov/diabetes/statistics/prev/national/figpersons.htm.
3. Narayan K.M., Boyle J.P., Geiss L.S., et al. Impact of recent increase in incidence on future diabetes burden: U.S., 2005-2050. Diabetes Care 2006, 29:2114-2116.
4. Selvin E., Coresh J., Brancati F.L. The burden and treatment of diabetes in elderly individuals in the U.S. Diabetes Care 2006, 29:2415-2419.
5. Standards of medical care in diabetes-2011. Diabetes Care 2011, 34(Suppl 1):S11-S61. American Diabetes Association.
6. Brown A.F., Mangione C.M., Saliba D., Sarkisian C.A. Guidelines for improving the care of the older person with diabetes mellitus. J Am Geriatr Soc 2003, 51(Suppl 5):S265-S280.
7. Miller C.K., Edwards L., Kissling G., Sanville L. Evaluation of a theory-based nutrition intervention for older adults with diabetes mellitus. J Am Dent Assoc 2002, 102:1069-1081.
8. Rodbard H.W., Jellinger P.S., Davidson J.A., et al. Statement by an American Association of Clinical Endocrinologists/American College of Endocrinology consensus panel on type 2 diabetes mellitus: an algorithm for glycemic control. Endocr Pract 2009, 15:540-559.
9. Nathan D.M., Buse J.B., Davidson M.B., et al. Management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2006, 29:1963-1972.
10. Gerstein H.C., Miller M.E., Byington R.P., et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008, 358:2545-2559.
11. Chiniwala N., Jabbour S. Management of diabetes mellitus in the elderly. Curr Opin Endocrinol Diabetes Obes 2011, 18:148-152.
12. Gall M.A., Hougaard P., Borch-Johnsen K., Parving H.H. Risk factors for development of incipient and overt diabetic nephropathy in patients with non-insulin dependent diabetes mellitus: prospective, observational study. BMJ 1997, 314:783-788.
13. de Zeeuw D., Remuzzi G., Parving H.H., et al. Albuminuria, a therapeutic target for cardiovascular protection in type 2 diabetic patients with nephropathy. Circulation 2004, 110:921-927.
14. Gerstein H.C., Mann J.F., Yi Q., et al. Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals. JAMA 2001, 286:421-426.
15. Stamler J., Vaccaro O., Neaton J.D., Wentworth D. Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the multiple risk factor intervention trial. Diabetes Care 1993, 16:434-444.
16. Bertoni A.G., Hundley W.G., Massing M.W., et al. Heart failure prevalence, incidence, and mortality in the elderly with diabetes. Diabetes Care 2004, 27:699-703.
17. Shorr R.I., Ray W.A., Daugherty J.R., Griffin M.R. Incidence and risk factors for serious hypoglycemia in older persons using insulin or sulfonylureas. Arch Intern Med 1997, 157:1681-1686.
18. Matyka K., Evans M., Lomas J., et al. Altered hierarchy of protective responses against severe hypoglycemia in normal aging in healthy men. Diabetes Care 1997, 20:135-141.
19. Fravel M.A., McDanel D.L., Ross M.B., et al. Special considerations for treatment of type 2 diabetes mellitus in the elderly. Am J Health Sys Pharm 2011, 68:500-509.
20. Clinical guideline for pharmacological management of type 2 diabetes Joslin Diabetes Center and Joslin Clinic, Accessed March 10, 2011. http://www.joslin.org/bin_from_cms/Pharma_guideline_11._10.pdf.
21. Facts & Comparisons® eAnswers Accessed October 26, 2011. http://online.factsandcomparisons.com/.
22. Rodbard H.W., Blonde L., Braithwaite S.S., et al. American Association of Clinical Endocrinologists medical guidelines for clinical practice for the management of diabetes mellitus. Endocr Pract 2007, 13(Suppl 1):1-68.
23. Pradhan A.D., Everett B.M., Cook N.R., et al. Effects of initiating insulin and metformin on glycemic control and inflammatory biomarkers among patients with type 2 diabetes: the LANCET randomized trial. JAMA 2009, 302:1186-1194.
24. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998, 352:854-865. UK Prospective Diabetes Study Group.
25. Hoffmann J., Spengler M. Efficacy of 24-week monotherapy with acarbose, metformin, or placebo in dietary-treated NIDDM patients: the Essen-II Study. Am J Med 1997, 103:483-490.
26. Johansen K. Efficacy of metformin in the treatment of NIDDM. Meta-analysis. Diabetes Care 1999, 22:33-37.
27. Kahn S.E., Haffner S.M., Heise M.A., et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 2006, 355:2427-2443.
28. Glucophage (metformin hydrochloride) tablets 2010, [prescribing information], Bristol-Myers Squibb Co, Princeton, NJ.
29. Neumiller J.J., Setter S.M. Pharmacologic management of the older patient with type 2 diabetes mellitus. Am J Geriatr Pharmacother 2009, 7:324-342.
30. Information for healthcare professionals rosiglitazone maleate (marketed as Avandia, Avandamet, and Avandaryl) US Food and Drug Administration, Accessed September 16, 2011. http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm143406.htm#2007_5.
31. Gerstein H.C., Yusuf S., Bosch J., et al. Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial. Lancet 2006, 368:1096-1105.
32. Aronoff S., Rosenblatt S., Braithwaite S., et al. Pioglitazone hydrochloride monotherapy improves glycemic control in the treatment of patients with type 2 diabetes: a 6-month randomized placebo-controlled dose-response study. The Pioglitazone 001 Study Group. Diabetes Care 2000, 23:1605-1611.
33. Gegick C.G., Altheimer M.D. Comparison of effects of thiazolidinediones on cardiovascular risk factors: observations from a clinical practice. Endocr Pract 2001, 7:162-169.
34. Home P.D., Pocock S.J., Beck-Nielsen H., et al. Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial. Lancet 2009, 373:2125-2135.
35. Pioglitazone HCl (marketed as Actos, Actoplus Met, and Duetact) information US Food and Drug Administration, Accessed September 16, 2011. http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm109136.htm.
36. Nathan D.M., Buse J.B., Davidson M.B., et al. Management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: update regarding thiazolidinediones: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2008, 31:173-175.
37. Lipscombe L.L., Gomes T., Levesque L.E., et al. Thiazolidinediones and cardiovascular outcomes in older patients with diabetes. JAMA 2007, 298:2634-2643.
38. Kahn S.E., Zinman B., Lachin J.M., et al. Rosiglitazone-associated fractures in type 2 diabetes: an Analysis from A Diabetes Outcome Progression Trial (ADOPT). Diabetes Care 2008, 31:845-851.
39. Solomon D.H., Cadarette S.M., Choudhry N.K., et al. A cohort study of thiazolidinediones and fractures in older adults with diabetes. J Clin Endocrinol Metab 2009, 94:2792-2798.
40. Simonson D.C., Kourides I.A., Feinglos M., et al. Efficacy, safety, and dose-response characteristics of glipizide gastrointestinal therapeutic system on glycemic control and insulin secretion in NIDDM. Results of two multicenter, randomized, placebo-controlled clinical trials. Diabetes Care 1997, 20:597-606.
41. Starlix (nateglinide) tablets 2010, [prescribing information], Novartis Pharmaceuticals, East Hanover, NJ.
42. Prandin (repaglinide) tablets (0.5, 1 and 2 mg) 2010, [prescribing information], Novo Nordisk Inc, Princeton, NJ.
43. Malaisse W.J. Mechanism of action of a new class of insulin secretagogues. Exp Clin Endocrinol Diabetes 1999, 107(Suppl 4):S140-S143.
44. Hollander P.A., Schwartz S.L., Gatlin M.R., et al. Nateglinide, but not glyburide, selectively enhances early insulin release and more effectively controls post-meal glucose excursions with less total insulin exposure [abstract]. Diabetes 2000, 49(Suppl 1):A111. Abstract 449-P.
45. Schwarz S.L., Gerich J.E., Marcellari A., et al. Nateglinide, alone or in combination with metformin, is effective and well tolerated in treatment-naive elderly patients with type 2 diabetes. Diabetes Obes Metab 2008, 10:652-660.
46. Rosenstock J., Hassman D.R., Madder R.D., et al. Repaglinide versus nateglinide monotherapy: a randomized, multicenter study. Diabetes Care 2004, 27:1265-1270.
47. Puls W., Keup U., Krause H.P., et al. Glucosidase inhibition. A new approach to the treatment of diabetes, obesity, and hyperlipoproteinaemia. Naturwissenschaften 1977, 64:536-537.
48. Fischer S., Hanefeld M., Spengler M., et al. European study on dose-response relationship of acarbose as a first-line drug in non-insulin-dependent diabetes mellitus: efficacy and safety of low and high doses. Acta Diabetol 1998, 35:34-40.
49. Inzucchi S.E., Maggs D.G., Spollett G.R., et al. Efficacy and metabolic effects of metformin and troglitazone in type II diabetes mellitus. N Engl J Med 1998, 338:867-872.
50. Josse R.G., Chiasson J.L., Ryan E.A., et al. Acarbose in the treatment of elderly patients with type 2 diabetes. Diabetes Res Clin Pract 2003, 59:37-42.
51. Meneilly G.S., Ryan E.A., Radziuk J., et al. Effect of acarbose on insulin sensitivity in elderly patients with diabetes. Diabetes Care 2000, 23:1162-1167.
52. Phung O.J., Scholle J.M., Talwar M., Coleman C.I. Effect of noninsulin antidiabetic drugs added to metformin therapy on glycemic control, weight gain, and hypoglycemia in type 2 diabetes. JAMA 2010, 303:1410-1418.
53. Bolen S., Feldman L., Vassy J., et al. Systematic review: comparative effectiveness and safety of oral medications for type 2 diabetes mellitus. Ann Intern Med 2007, 147:386-399.
54. Nauck M.A., Bartels E., Orskov C., et al. Additive insulinotropic effects of exogenous synthetic human gastric inhibitory polypeptide and glucagon-like peptide-1-(7-36) amide infused at near-physiological insulinotropic hormone and glucose concentrations. J Clin Endocrinol Metab 1993, 76:912-917.
55. Nauck M.A., Niedereichholz U., Ettler R., et al. Glucagon-like peptide 1 inhibition of gastric emptying outweighs its insulinotropic effects in healthy humans. Am J Physiol Endocrinol Metab 1997, 273:E981-E988.
56. Willms B., Werner J., Holst J.J., et al. Gastric emptying, glucose responses, and insulin secretion after a liquid test meal: effects of exogenous glucagon-like peptide-1 (GLP-1)-(7-36) amide in type 2 (noninsulin-dependent) diabetic patients. J Clin Endocrinol Metab 1996, 81:327-332.
57. Nauck M.A., Meier J.J. Individualised incretin-based treatment for type 2 diabetes. Lancet 2010, 376:393-394.
58. Zander M., Madsbad S., Madsen J.L., Holst J.J. Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and b-cell function in type 2 diabetes: a parallel-group study. Lancet 2002, 359:824-830.
59. Pratley R.E., Gilbert M. Targeting incretins in type 2 diabetes: role of GLP-1 receptor agonists and DPP-4 inhibitors. Rev Diabet Stud 2008, 5:73-94.
60. Vilsboll T. Liraglutide: a once-daily GLP-1 analogue for the treatment of type 2 diabetes mellitus. Expert Opin Invest Drugs 2007, 16:231-237.
61. Moretto T.J., Milton D.R., Ridge T.D., et al. Efficacy and tolerability of exenatide monotherapy over 24 weeks in antidiabetic drug-naive patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, parallel-group study. Clin Ther 2008, 30:1448-1460.
62. 365 and <65 years of age: a pooled analysis from phase 3 studies. Am J Geriatr Pharmacother 2011, in press.
63. Vilsboll T., Zdravkovic M., Le-Thi T., et al. Liraglutide, a long-acting human GLP-1 analog, given as monotherapy significantly improves glycemic control and lowers body weight without risk of hypoglycemia in patients with type 2 diabetes mellitus. Diabetes Care 2007, 30:1608-1610.
64. Fehse F., Trautmann M., Holst J.J., et al. Exenatide augments first- and second-phase insulin secretion in response to intravenous glucose in subjects with type 2 diabetes. J Clin Endocrinol Metab 2005, 90:5991-5997.
65. Garber A., Henry R., Ratner R., et al. Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial. Lancet 2009, 373:473-481.
66. Ban K., Noyan-Ashraf M.H., Hoefer J., et al. Cardioprotective and vasodilatory actions of glucagon-like peptide 1 receptor are mediated through both glucagon-like peptide 1 receptor-dependent and -independent pathways. Circulation 2008, 117:2340-2350.
67. Wang G.J., Tomasi D., Backus W., et al. Gastric distention activates satiety circuitry in the human brain. Neuroimage 2008, 39:1824-1831.
68. Byetta (exenatide injection) 2010, [prescribing information], Amylin Pharmaceuticals, Inc, San Diego, Calif.
69. Banks P.A., Freeman M.L. Practice guidelines in acute pancreatitis. Am J Gastroenterol 2006, 101:2379-2400.
70. Victoza (liraglutide [rDNA origin] injection), solution for subcutaneous use 2011, [prescribing information], Novo Nordisk Inc, Princeton, NJ.
71. Buse J.B., Rosenstock J., Sesti G., et al. Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6). Lancet 2009, 374:39-47.
72. Davidson J.A., Brett J., Falahati A., Scott D. Mild renal impairment and the efficacy and safety of liraglutide. Endocr Pract 2010, 17:345-355.
73. Drucker D.J., Sherman S.I., Bergenstal R.M., Buse J.B. The safety of incretin-based therapies-review of the scientific evidence. J Clin Endocrinol Metab 2011, 96:2027-2031.
74. Parks M., Rosebraugh C. Weighing risks and benefits of liraglutide-the FDA's review of a new antidiabetic therapy. N Engl J Med 2010, 362:774-777.
75. Bjerre K.L., Madsen L.W., Andersen S., et al. Glucagon-like Peptide-1 receptor agonists activate rodent thyroid C-cells causing calcitonin release and C-cell proliferation. Endocrinology 2010, 151:1473-1486.
76. Buse J.B., Sesti G., Schmidt W.E., et al. Switching to once-daily liraglutide from twice-daily exenatide further improves glycemic control in patients with type 2 diabetes using oral agents. Diabetes Care 2010, 33:1300-1303.
77. Schweizer A., Dejager S., Bosi E. Comparison of vildagliptin and metformin monotherapy in elderly patients with type 2 diabetes: a 24-week, double-blind, randomized trial. Diabet Obes Metab 2009, 11:804-812.
78. Januvia (sitagliptin) tablets 2010, [prescribing information], Merck & Co Inc, Whitehouse Station, NJ.
79. Rosenstock J., Aguilar-Salinas C., Klein E., et al. Effect of saxagliptin monotherapy in treatment-naive patients with type 2 diabetes. Curr Med Res Opin 2009, 25. 2401-2011.
80. Taskinen M.R., Rosenstock J., Tamminen I., et al. Safety and efficacy of linagliptin as add-on therapy to metformin in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled study. Diabetes Obes Metab 2011, 13:65-74.
81. Aschner P., Kipnes M.S., Lunceford J.K., et al. Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes. Diabetes Care 2006, 29:2632-2637.
82. Stafford S., Elahi D., Meneilly G.S. Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin in older adults with type 2 diabetes mellitus. J Am Geriatr Soc 2011, 59:1148-1149.
83. Doucet J., Chacra A., Maheux P., et al. Efficacy and safety of saxagliptin in older patients with type 2 diabetes mellitus. Curr Med Res Opin 2011, 27:863-869.
84. Onglyza (saxagliptin) tablets 2009, [prescribing information], Bristol-Myers Squibb, Princeton, NJ.
85. Tradjenta(TM) (linagliptin) tablets 2011, [prescribing information], Boehringer-Ingelheim International GmbH, Germany.
86. Amori R.E., Lau J., Pittas A.G. Efficacy and safety of incretin therapy in type 2 diabetes: systematic review and meta-analysis. JAMA 2007, 298:194-206.
87. Information for healthcare professionals-acute pancreatitis and sitagliptin (marketed as Januvia and Janumet) Food and Drug Administration, Accessed September 16, 2011. http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/DrugSafetyInformationforHeathcareProfessionals/ucm183764.htm.
88. Pratley R.E., Rosenstock J., Pi-Sunyer F.X., et al. Management of type 2 diabetes in treatment-naive elderly patients: benefits and risks of vildagliptin monotherapy. Diabetes Care 2007, 30:3017-3022.
89. Pratley R.E., McCall T., Fleck P.R., et al. Alogliptin use in elderly people: a pooled analysis from phase 2 and 3 studies. J Am Geriatr Soc 2009, 57:2011-2019.
90. Schwartz S.L. Treatment of elderly patients with type 2 diabetes mellitus: a systematic review of the benefits and risks of dipeptidyl peptidase-4 inhibitors. Am J Geriatr Pharmacother 2010, 8:405-418.
91. Mathieu C., Bollaerts K. Antihyperglycaemic therapy in elderly patients with type 2 diabetes: potential role of incretin mimetics and DPP-4 inhibitors. Int J Clin Pract 2007, 61:29-37.
92. Bourdel-Marchasson I., Schweizer A., Dejager S. Incretin therapies in the management of elderly patients with type 2 diabetes mellitus. Hospital Practice (Minneap) 2011, 39:7-21.
93. Pratley R.E., Nauck M., Bailey T., et al. Liraglutide versus sitagliptin for patients with type 2 diabetes who did not have adequate glycaemic control with metformin: a 26-week, randomised, parallel-group, open-label trial. Lancet 2010, 375:1447-1456.
94. Degn K.B., Brock B., Juhl C.B., et al. Effect of intravenous infusion of exenatide (synthetic exendin-4) on glucose-dependent insulin secretion and counterregulation during hypoglycemia. Diabetes 2004, 53:2397-2403.
95. Mari A., Sallas W.M., He Y.L., et al. Vildagliptin, a dipeptidyl peptidase-IV inhibitor, improves model-assessed b-cell function in patients with type 2 diabetes. J Clin Endocrinol Metab 2005, 90:4888-4894.